Avalo Therapeutics, Inc. has entered into a Sales Agreement with TD Securities $(USA)$ LLC, allowing the company to offer and sell shares of its common stock valued up to $75 million. The issuance and sale of these shares will be conducted under a previously filed Registration Statement with the Securities and Exchange Commission, which became effective on May 2, 2023. The offering will continue until all shares are sold or the agreement is terminated. This new agreement follows a previous arrangement with Oppenheimer & Co. Inc., which allowed for the sale of shares worth up to $50 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.